{
  "drug_name": "Bivalirudin",
  "url": "https://wikem.org/wiki/Bivalirudin",
  "scraped_at": "2026-01-10T07:48:52.302639",
  "sections": {
    "Administration": {
      "text": "Type:\nAnticoagulant\n(Direct thrombin inhibitor)\nDosage Forms: powder for injection\nDosage Strengths: 250mg\nRoutes of Administration: IV\nCommon Trade Names: Angiomax, Angiox",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Anticoagulant",
          "url": "https://wikem.org/wiki/Anticoagulant"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "Acute MI, adjunct to thrombolysis: 0.25 mg/kg IV bolus + 0.5 mg/kg/hr x 12h, then 0.25 mg/kg/hr x 36h\nPCI Thrombosis prophylaxis: 0.75 mg/kg IV bolus + 1.75 mg/kg/hr IV infusion during procedure + 0.2mg/kg/hr x 4-20h after procedure\nUnstable angina/NSTEMI: 0.1 mg/kg IV bolus + 0.25 mg/kg/hour IV infusion",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "Safety/efficacy not established",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: B\nLactation risk\n: Infant risk cannot be ruled out\nRenal dosing: no adjustment in bolus dosing\nCrCl 30-59 mL/min: no adjustment in infusion or bolus dose\nCrCl <30: consider reducing infusion to 1 mg/kg/hr\nHemodialysis: Reduce infusion rate to 0.25 mg/kg/hr\nHepatic dosing:",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nActive major bleeding",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Major bleeding: retroperitoneal, intracranial hemorrhage\nCoronary artery stent thrombosis, ventricular fibrillation\nThrombosis\nCerebral ischemia\nPeripheral facial palsy\nOliguria, renal failure\nSepsis",
          "tables": []
        },
        "Common": {
          "text": "Hypotension\nMinor bleeding\nNausea\nHeadache, backache, pain",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "Major bleeding: retroperitoneal, intracranial hemorrhage\nCoronary artery stent thrombosis, ventricular fibrillation\nThrombosis\nCerebral ischemia\nPeripheral facial palsy\nOliguria, renal failure\nSepsis",
      "subsections": {
        "Common": {
          "text": "Hypotension\nMinor bleeding\nNausea\nHeadache, backache, pain",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Common": {
      "text": "Hypotension\nMinor bleeding\nNausea\nHeadache, backache, pain",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 25 min\nMetabolism: Blood proteases\nExcretion: Renal",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "Binds to and inhibits thrombin",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Coagulopathy (main)\nAnticoagulant reversal for life-threatening bleeds",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Coagulopathy (main)",
          "url": "https://wikem.org/wiki/Coagulopathy_(main)"
        },
        {
          "text": "Anticoagulant reversal for life-threatening bleeds",
          "url": "https://wikem.org/wiki/Anticoagulant_reversal_for_life-threatening_bleeds"
        }
      ]
    },
    "References": {
      "text": "Allie DE, Lirtzman MD, Wyatt CH, et al, “Bivalirudin as a Foundation Anticoagulant in Peripheral Vascular Disease: A Safe and Feasible Alternative for Renal and Iliac Interventions,\" J Invasive Cardiol, 2003, 15(6):334-42. [PubMed 12777673]\nAmsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. J Am Coll Cardiol. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017. [PubMed 25260718]\nAngiomax (bivalirudin) [prescribing information]. Princeton, NJ: Sandoz Inc; February 2019.\nAngiomax (bivalirudin) [product monograph]. Mississauga, Ontario, Canada: Sunovion Pharmaceuticals Canada Inc.; September 2016.\nAntman EM, “Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions?” JAMA, 2003, 289:903-5. [PubMed 12588276]\nAggarwal A, Sobel BE, and Schneider DJ, “Decreased Platelet Reactivity in Blood Anticoagulated With Bivalirudin or Enoxaparin Compared With Unfractionated Heparin: Implications for Coronary Intervention,” J Thromb Thrombolysis, 2002, 13:161-5. [PubMed 12355033]\nBittl JA, Chaitman BR, Feit F, et al, “Bivalirudin Versus Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina: Final Report Reanalysis of the Bivalirudin Angioplasty Study,” Am Heart J, 2001, 142:952-9. [PubMed 11717596]\nBittl JA, Strony J, Brinker JA, et al, “Treatment With Bivalirudin (Hirulog) as Compared With Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina. Hirulog Angioplasty Study Investigators,” N Engl J Med, 1995, 333(12):764-9. [PubMed 7643883]\nBivalirudin injection [prescribing information]. Deerfield, IL: Baxter Healthcare; May 2018.\nCuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489. [PubMed 30482768]",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}